Tested drug for acute ischemic stroke within 24 hours
Part of Brain & nervous system, Heart & circulation clinical trials.
This Phase 3 trial studies sovateltide (and a placebo) in adults with an ischemic stroke, aiming to improve safety and outcomes. It focuses on people who can start treatment quickly after stroke symptoms begin and who do not have bleeding in the brain on imaging.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 80 years old
- Have an ischemic stroke (a blood-flow blockage), confirmed by CT or MRI, with NO bleeding seen on the scan
- Be able to start the first dose within 24 hours of when symptoms began (or last seen normal, if symptoms were during sleep)
- Have moderate stroke severity on screening (NIHSS score at least 8 but less than 20, and consciousness level not too impaired)
- Be able to attend the full treatment course and follow-up visits
- Be willing and able to give consent (as required by local laws and the study’s ethics rules)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a clot-busting drug called tenecteplase directly into the blocked blood vessel in the brain can help people with a medium-sized vessel occlusion stroke. The drug may help restore blood flow and reduce disability, and it is given within 24 hours of symptom onset.
This trial tests whether adding a medication called sivelestat sodium to emergency clot removal surgery (mechanical thrombectomy) can improve outcomes in patients with a specific type of stroke caused by a large blood clot in the front part of the brain. The goal is to see if this combination treatment leads to better recovery.
This study tests an investigational injectable drug called LT3001 that may help dissolve blood clots in the brain after a stroke. It is given within 24 hours of stroke onset, and the goal is to reduce disability and improve recovery.
This Phase 2 study tests LT3001 to improve recovery after an acute ischemic stroke (a stroke caused by blocked blood flow). It is designed for people who can be treated within 24 hours of symptom onset and who meet specific safety and health requirements.
This trial tests if the clot-busting drug tenecteplase is safe and effective for people having an ischemic stroke who have recently taken blood thinners (DOACs). If you qualify, you may receive either tenecteplase or a placebo within 24 hours of your last known well time.
This trial tests a medication called tirofiban given intravenously after standard thrombolysis to see if it improves recovery in people with acute ischemic stroke. It is for those whose symptoms have not improved or are getting worse after initial treatment.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.